TF-505 | CAS#146939-64-2

MedKoo Cat#: 530203 | Name: TF-505

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TF-505, also known as FK-687; FR-146687, is a steroid 5α-reductase inhibitor potentially for the treatment of benign prostatic hyperplasia.

Chemical Structure

TF-505

CAS#146939-64-2

Theoretical Analysis

MedKoo Cat#: 530203

Name: TF-505

CAS#: 146939-64-2

Chemical Formula: C33H37NO4

Exact Mass: 511.2723

Molecular Weight: 511.66

Elemental Analysis: C, 77.47; H, 7.29; N, 2.74; O, 12.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TF-505; TF 505; FK-687; FR-146687; TF505; FK687; FR146687.

IUPAC/Chemical Name

(S)-4-(1-(4-(1-(4-isobutylphenyl)butoxy)benzoyl)indolizin-3-yl)butanoic acid

InChi Key

InChi Code

SMILES Code

CC[C@@H](C1=CC=C(CC(C)C)C=C1)OC2=CC=C(C=C2)C(C3=C4N(C(CCCC(O)=O)=C3)C=CC=C4)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 511.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yao Z, Krzyzanski W, Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn. 2006 Apr;33(2):167-93. PubMed PMID: 16547797. 2: Matsumoto Y, Fujita T, Ishida Y, Shimizu M, Kakuo H, Yamashita K, Majima M, Kumagai Y. Population pharmacokinetic-pharmacodynamic modeling of TF-505 using extension of indirect response model by incorporating a circadian rhythm in healthy volunteers. Biol Pharm Bull. 2005 Aug;28(8):1455-61. PubMed PMID: 16079492. 3: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. March 2003. Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):145-68. PubMed PMID: 12731460. 4: Fujita T, Matsumoto Y, Kimura T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94. PubMed PMID: 12236849; PubMed Central PMCID: PMC1874425. 5: Nakayama O, Hirosumi J, Chida N, Takahashi S, Sawada K, Kojo H, Notsu Y. FR146687, a novel steroid 5 alpha-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate. 1997 Jun 1;31(4):241-9. PubMed PMID: 9180934.